EP1506019A1 - Complexes for the delivery of biologically-active material to cells - Google Patents
Complexes for the delivery of biologically-active material to cellsInfo
- Publication number
- EP1506019A1 EP1506019A1 EP03730315A EP03730315A EP1506019A1 EP 1506019 A1 EP1506019 A1 EP 1506019A1 EP 03730315 A EP03730315 A EP 03730315A EP 03730315 A EP03730315 A EP 03730315A EP 1506019 A1 EP1506019 A1 EP 1506019A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- complex according
- same
- different
- complex
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011149 active material Substances 0.000 title claims abstract description 36
- 150000002632 lipids Chemical class 0.000 claims abstract description 83
- 125000001424 substituent group Chemical group 0.000 claims abstract description 30
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 23
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 18
- 150000002367 halogens Chemical class 0.000 claims abstract description 18
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 99
- 150000007523 nucleic acids Chemical class 0.000 claims description 82
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 67
- 108010044426 integrins Proteins 0.000 claims description 52
- 102000006495 integrins Human genes 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 108091026890 Coding region Proteins 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000007935 neutral effect Effects 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 230000000692 anti-sense effect Effects 0.000 claims description 15
- -1 stearic Chemical group 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000001273 butane Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 230000009395 genetic defect Effects 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000005017 genetic modification Effects 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- DXYNJHYPRKUMLM-WRBBJXAJSA-N 2,3-bis[(z)-octadec-9-enoxy]propyl-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-dimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCOCCOCCO)OCCCCCCCC\C=C/CCCCCCCC DXYNJHYPRKUMLM-WRBBJXAJSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 17
- 238000001415 gene therapy Methods 0.000 abstract description 15
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 108091033319 polynucleotide Proteins 0.000 description 39
- 102000040430 polynucleotide Human genes 0.000 description 39
- 239000002157 polynucleotide Substances 0.000 description 39
- 239000013598 vector Substances 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 108091034117 Oligonucleotide Proteins 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 125000002091 cationic group Chemical group 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 150000001450 anions Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229920006317 cationic polymer Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000029570 hepatitis D virus infection Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- SJLOJIPERLOOGE-WRBBJXAJSA-N 2,3-bis[(z)-octadec-9-enoxy]propyl-(3-bromopropyl)-dimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCBr)OCCCCCCCC\C=C/CCCCCCCC SJLOJIPERLOOGE-WRBBJXAJSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- JYRDRGOLCZHQJZ-UHFFFAOYSA-N 2-[2-(2-bromoethoxy)ethoxy]ethanol Chemical compound OCCOCCOCCBr JYRDRGOLCZHQJZ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 108091027075 5S-rRNA precursor Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000004881 Amebiasis Diseases 0.000 description 2
- 206010001980 Amoebiasis Diseases 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 206010044608 Trichiniasis Diseases 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 125000005642 phosphothioate group Chemical group 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920002851 polycationic polymer Polymers 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000003982 trichinellosis Diseases 0.000 description 2
- 201000007588 trichinosis Diseases 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- HFIUNERSXYKHSP-UHFFFAOYSA-N 1,4-dibromobutane-1,1-diol Chemical compound OC(O)(Br)CCCBr HFIUNERSXYKHSP-UHFFFAOYSA-N 0.000 description 1
- XOWDQAHYPSENAC-UHFFFAOYSA-N 1,4-dibromobutane-2,3-diol Chemical compound BrCC(O)C(O)CBr XOWDQAHYPSENAC-UHFFFAOYSA-N 0.000 description 1
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710172562 Cobra venom factor Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000931304 Eriachne Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 101710198693 Invasin Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000122938 Strongylus vulgaris Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- SFCVHVDJESFESU-KHPPLWFESA-N [(z)-octadec-9-enyl] methanesulfonate Chemical compound CCCCCCCC\C=C/CCCCCCCCOS(C)(=O)=O SFCVHVDJESFESU-KHPPLWFESA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000029719 integrin binding proteins Human genes 0.000 description 1
- 108091009291 integrin binding proteins Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a complex suitable for delivery of a biologically-active material, for example nucleic acids, proteins and small molecules, to a cell.
- a biologically-active material for example nucleic acids, proteins and small molecules
- the invention also relates to the use of such complexes in the delivery of biologically-active material to a cell, for example in prophylaxis, treatment and vaccination.
- the invention relates to lipids which may be used in the complexes of the invention.
- Gene delivery for therapy or other purposes is of course well-known, particularly for the treatment of diseases such as cystic fibrosis and certain cancers.
- the term refers to the delivery into a cell of a gene or part of a gene to correct some deficiency.
- the term is used also to refer to any introduction of nucleic acid material into target cells, and includes gene vaccination and the in vitro production of commercially-useful proteins in so-called cell factories.
- Cell delivery systems fall into three broad classes, namely those that involve direct injection of naked DNA, those that make use of viruses or alternated viruses and those that make use of non- viral delivery agents. Each has its advantages and disadvantages. Although viruses as delivery agents have the advantages of high efficiency and high cell selectivity, they have the disadvantages of toxicity, production of inflammatory responses and difficulty in dealing with large DNA fragments.
- the present invention in making use of lipids, can overcome these problems.
- Cationic lipids for use in gene delivery were developed by Feigner in the late 1980s, and reported in Proc. Natl. Acad. Sci. USA 84, 7413-7417, 1987.
- a recent patent to Feigner et al. that may be referred to is US 5264618. The disclosure of each of these documents is incorporated herein by reference.
- Feigner developed the now commercially-available cationic liposome known by the trade mark "Lipofectin" which consists of the cytofectin, DOTMA and the neutral lipid DOPE in a 1 : 1 ratio.
- Various other cationic liposome formulations have since been devised, most of which combine a synthetic cationic cytofectin and a neutral lipid.
- LID vectors are three component vectors consisting of an integrin binding peptide, a lipid or lipid mixture such as Lipofectin and DNA. Specificity results from the targeting of the integrin, and transfection efficiencies comparable to some adenoviral vectors can be achieved (Hart et al, Hum. Gene Ther. 9, 1037-47, 1998; Harbottle et al. Hum. Gene. Ther. 9, 575-85, 1998; and Jenkins et al. Gene Therapy 7, 393-400, 2000, the disclosures of which are incorporated herein by reference).
- Cytofectins are positively charged molecules having a cationic head group attached via some spacer to a hydrophobic tail.
- DOTMA analogues there may be mentioned complex alkylamine/alkylamides, cholesterol derivatives, and synthetic derivatives of dipalmitol, phosphatidyl-ethanolamine, glutamate, imidazole and phosphonate.
- a review of these materials, and of the mechanisms by which they operate, may be found in Angew. Chem. Int. Ed. 32 1768-1785, 1998, the disclosure of which is incorporated herein by reference.
- the nucleic acid must be delivered in a form in which it will be taken up, or internalised, by the target cell and allow it to be expressed properly. Also, the nucleic acid must, in general, be protected against certain cellular enzymes such as nucleases, and for in vivo applications have suitable stability to serum. Thus, one must consider both internalization and protection when designing a lipid vector. We have devised certain new dicationic lipids and also certain new PEG- based lipids incorporating a spacer between cationic centres
- a complex suitable for delivery of a biologically-active material to a cell which complex comprises:
- - X 1 and X 2 are the same or different and are selected from -O-CH 2 -, and
- R 1 and R 2 are the same or different and are straight or branched, saturated or unsaturated C 7 to C 24 hydrocarbyl groups which are unsubstituted or substituted by one or more substituents selected from hydroxy, halogen and OR', wherein R' is a C x to C 6 hydrocarbyl group; - each R 3 and each R 4 is the same or different and is a straight or branched, saturated or unsaturated C j to C ⁇ 0 hydrocarbyl group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen, -OR', -C(O)OH, -CN, -NR'R", and -C(O)R" wherein R' and R" are the same or different and are C x to C 6 hydrocarbyl;
- - X 1 and X 2 are the same or different and are as defined above;
- R 1 and R 2 are the same or different and are as defined above;
- - R 5 is -N ffi (R 3 ) 2 -R 6 wherein each R 3 is the same or different and is as defined above and R 6 is either
- each Y is the same or different and is -N ⁇ (R 4 ) 2 -, wherein R 4 is as defined above, each A is the same or different and is a C x to C 20 alkylene group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen, -OR', -C(O)OH, -CN, -NR'R", and -C(O)R" wherein R' and R" are the same or different and are C to C 6 hydrocarbyl, n is from 1 to 10, and R 4 is as defined above; or
- each B is the same or different and is a Cj to C 10 alkylene group which is unsubstituted or substituted by one or more substituents selected from hydroxy, halogen, -OR', -C(O)OH, -CN, -NR'R" and -C(O)R" wherein R' and R" are the same or different and are to C 6 hydrocarbyl, m is from 1 to 10, and
- Q is selected from N ⁇ (R 3 ) 3 , OH, OR', OC(O)R' and halogen, wherein R 3 and R' are as defined above; and (ii) a biologically-active material.
- the invention also provides:
- a process for the preparation of a complex of the invention comprises: admixing (i) a lipid of formula (I) or (II) as defined above; and (ii) a biologically-active material;
- a method for transfecting a cell with a biologically-active material comprises contacting the cell in vivo, in vitro or ex vivo with a complex of the invention
- - a method for the expression of a nucleic acid in a cell, which method comprises transfecting the cell with a complex of the invention using the method set out above under conditions to provide for expression of the nucleic acid component of the complex; - a method for the preparation of a polypeptide, which method comprises:
- composition comprising a complex of the invention and a pharmaceutically-acceptable carrier, diluent or excipient;
- - a method for the treatment of a condition caused by or related to a genetic defect or modification in a host, which method comprises administering to the host a therapeutically effective amount of a complex of the invention
- - a method for the treatment of a condition in a host by an anti-sense nucleic acid or an iRNA, which method comprises administering to the host a therapeutically effective amount of a complex of the invention
- a vaccine comprising a complex of the invention and a pharmaceutically- acceptable carrier, diluent or excipient; - a complex of the invention for use in a method of vaccinating a human or animal;
- the invention relates to complexes suitable for the delivery of a biologically- active material to a cell.
- the complexes are based on new lipids.
- the complexes of the invention may be used, for example, in gene therapy and vaccination. Gene therapy may be carried out, for example, to correct a genetic defect of modification.
- the orientation of the X 1 and X 2 moieties is such that the right hand side of the depicted moieties are attached to the group R 1 or R 2 .
- the lipid of formula (I) or (II) is, of course, cationic, and will be associated with one or more pharmaceutically acceptable anion.
- acceptable anions include anions of various mineral acids such as, for example, chloride, bromide, iodide, sulfate, nitrate, phosphate and anions of organic acids such as, for example, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate.
- Preferred anions are chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate and succinate.
- More preferred anions are bromide and iodide.
- X 1 and X 2 are typically the same. X 1 and X 2 are preferably -O-CH 2 -.
- unsaturated hydrocarbyl groups include alkenyl groups and alkynyl groups. Preferred unsaturated hydrocarbyl groups are alkenyl groups which contain one or more, for example one or two, double bonds, each of which may be cis or trans. Typically, unsaturated hydrocarbyl groups are alkenyl groups which contain one or two cis double bonds. Typically, a said hydrocarbyl group is unsubstituted.
- each R' and R" is the same or different and is a C x to C 6 alkyl group.
- R 1 and R 2 are the same or different and are straight or branched, saturated or unsaturated C 10 to C 22 hydrocarbyl groups which are unsubstituted or substituted as defined above. More preferably, R 1 and R 2 are the same or different and are straight or branched, saturated or unsaturated C 12 to C 20 hydrocarbyl groups which are unsubstituted or substituted as defined above. More preferably still, R 1 and
- R 1 and R 2 are the same. Typically, R 1 and R 2 are unsubstituted or carry one, two or three substituents. Preferably, R 1 and R 2 are unsubstituted.
- each R 3 and each R 4 is unsubstituted or substituted by one or more, for example one or two, substituents selected from hydroxy, -OR', -C(O)OH, -CN, - NR'R" and -C(O)R" wherein R' and R" are the same or different and are C j to C 6 hydrocarbyl.
- each R 3 and each R 4 are the same or different and are straight or branched, saturated or unsaturated C j to C 6 hydrocarbyl groups, for example C ⁇ to C 4 hydrocarbyl groups, which are unsubstituted or substituted by one or more substituents as defined above.
- each R 3 is the same.
- each R 4 is the same.
- each R 3 and each R 4 are the same.
- R 3 and R 4 are -C K , alkyl groups, for example C r C 6 and C r C 4 alkyl groups.
- R 3 and R 4 are methyl.
- R 3 and R 4 are typically unsubstituted or carry one or two substituents.
- Preferred R 3 and R 4 substituents are selected from hydroxy and -OR' wherein R' is a
- R 3 and R 4 are unsubstituted.
- n is from 1 to 5. More preferably, n is from 1 to 2. Typically, n is 1.
- m is from 1 to 5. More preferably, m is from 1 to 3. Typically, m is 1 or 2.
- A is C j to C 10 alkylene, for example C 3 , C 6 or C 10 alkylene, which is unsubstituted or substituted by one or more substituents as defined above. More preferably, A is C 2 to C 6 alkylene which is unsubstituted or substituted by one or more substituents as defined above. Yet more preferably, A is C 3 , C 4 or C 5 alkylene which is unsubstituted or substituted by one or more substituents as defined above.
- A is propylene which is unsubstituted or substituted by one or more substituents as defined above.
- A is unsubstituted or carries one or two substituents.
- Preferred substituents for A are selected from hydroxy, halogen and -OR' wherein R' is a C j to C 6 alkyl group. More preferably, A is unsubstituted.
- B is C x to C 5 alkylene which is unsubstituted or substituted by one or more substituents as defined above. More preferably, B is C 2 , C 3 or C 4 alkylene which is unsubstituted or substituted by one or more substituents as defined above. Most preferably, B is ethylene which is unsubstituted or substituted by one or more substituents as defined above.
- B is unsubstituted or carries one or two substituents.
- Preferred substituents for B are selected from hydroxy, halogen and -OR' wherein R' is a C j to C 6 alkyl group. More preferably, B is unsubstituted.
- Q is preferably -N ffi (R 3 ) 3 or OH. Typically, Q is -N ⁇ Me 3 or OH.
- the present invention also provides a composition including the structure
- Y is NH, CH 2 , O or N(acetyl);
- Z is O(C ⁇ to C 4 ), OC(O)R 3 , N ⁇ R 3 4 , OH, F, CI, Br or I
- R 3 is CI to C6 alkyl
- the R 4 s which may be the same or different, are CI to C6 chains
- n is from 2, 3 or 4
- m is from 1 to 200 and where it is at least 2 the resulting repeating units may be the same or different.
- R is hydrogen and the other is group (b); or that both groups R are groups (c).
- the lipid may be PEG- based, and in the second case it is based on erythritol.
- m is less than or equal to 100, more preferably less than of equal to 50, especially less than or equal to 25, more especially less than or equal to 12.
- m is at least 2.
- formula (III) set out above is cationic, it will be accompanied by one or more appropriate non-toxic anions.
- Suitable anions include halide, particularly iodide.
- the two groups R are substantially identical and/or that the two groups R 1 are substantially identical.
- the overall structure will be substantially symmetrical.
- the groups X in the formula (in) are OC
- the linkages will of course be ethers, and where the groups are O-C(O) the linkages will be esters.
- the ether structures are preferred because they seem to have greater activity.
- the chain length of the tails R 1 in the formula (III) has been investigated. Including the carbon atom of the linkage X, we prefer from CIO to C22, and preferably straight-chain. At present a value of about CI 6 or CI 8 seems to be optimum, although the precise value will depend on the application. Other possible values include C12, C14, and C20.
- the tails may be saturated or unsaturated, and when unsaturated may contain one or more double bonds, each of which may be cis or trans, and/or one or more triple bonds.
- Typical unsaturated structures include one or two cis double bonds. We have found higher transfection efficiencies with unsaturated lipids.
- Groups R 2 in the formula (III) are preferably straight chain alkyl, although branched groups can be acceptable. We prefer CI, C2, C3 and C4. The same applies to group R 3 . Although (when m is two or more) the repeating units [Y-(CH 2 )-] in the formula (III) may all be the same, we prefer that Y be CH 2 in all but one of them, and therefore that it take on one of the other possibilities in only one of the repeating units. Of these other possibilities, O is at present preferred.
- the number of methylene groups, n is preferably 2, although other values for example 1, 3, 4, 5 and 6 may be desirable in some circumstances.
- the lipids of the invention will contain one or more chiral centre.
- the two carbon atoms illustrated as such in the general formula given above will be chiral centres.
- there will be four isomers unless the structure has a plane of symmetry between those carbon atoms is which case there will be three isomers.
- the chemical structures depicted herein are intended to embrace all stereoisomers of the compounds shown, including racemic and non-racemic mixtures and pure enantiomers and/or diasteroisomers.
- the spacer to be reasonably short, for example from C2 to C6, and preferably C3, C4 or C5.
- the intention is that complexes be formed that are capable of entering the target cells, after which the nucleic acid can be released to be expressed in the cell nucleus or in some way to control or affect gene expression.
- the lipids of the invention may be formulated with one or more other components as complexes which are suitable for use in the delivery of a biologically- active material to a cell.
- complexes comprise a lipid of the invention and a biologically-active material.
- Complexes of the invention may also comprise one or more of: an integrin-binding peptide; a polycationic component; and a neutral lipid.
- Suitable biologically-active materials include nucleic acids, peptides and polypeptides, and small molecules.
- a biologically-active material is one which has a biological effect when introduced into a cell or host, for example by stimulating an immune response or an inflammatory response, by exerting enzymatic activity or by complementing a mutation, etc. These particular biological activities are given merely by way of examples and are not to be taken as limiting.
- nucleic acid and “polynucleotide” are used interchangeably and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
- Non-limiting examples of polynucleotides include a gene, a gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, cosmids, vectors, artificial chromosomes, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
- mRNA messenger RNA
- transfer RNA transfer RNA
- ribosomal RNA ribozymes
- cDNA recombinant polynucleotides
- branched polynucleotides branched polynucleotides
- plasmids plasmids
- cosmids vectors
- artificial chromosomes isolated DNA of any sequence
- isolated RNA of any sequence nucleic acid probes, and primers.
- Polynucleotides of the invention may include within them synthetic or modified nucleotides.
- a number of different types of modification to polynucleotides are known in the art. Such modifications may be carried out in order to enhance the in vivo activity, lifespan, nuclease resistance or ability to enter cells.
- phosphorothioate oligonucleotides may be used.
- Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methylribonucleotide methylphosphonates.
- MBOs Mixed backbone oligonucleotides
- MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed segments of modified oligodeoxy- or oligoribonucleotides.
- MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'- O-alkyloligoribonucleotides .
- a DNA in a complex of the invention may be in the form of a linear molecule or a circular molecule, for example a plasmid or cosmid.
- linear DNA molecules include DNA in the form of a chromosome or a mini chromosome.
- An RNA used in a complex of the invention may be polycistronic, i.e. may comprise more than one coding sequence, and therefore may comprise an internal ribosome entry site (IRES).
- a DNA for use in the invention comprises more than one DNA coding sequence
- those coding sequences may be operably linked to independent control sequences.
- the coding sequences may be operably linked to common control sequences, in which case the coding sequences may be separated by an (IRES).
- RNA in complex of the invention may be linear or circular, for example a replicon, in particular an alpha virus replicon.
- the RNA may be single stranded or double stranded.
- the RNA may be an mRNA.
- Suitable mRNAs will typically comprise a 5' cap and/or a 3' polyA tail.
- the length of the polyA tail may be modulated to regulate the stability of the mRNA within target cells and hence control the duration of transgene expression from the mRNA.
- a polyA tail of will be up to about 300 residues in length, preferably from about 50 to about 90 residues in length.
- a “gene” as used in the context of the present invention is a sequence of nucleotides in a genetic nucleic acid (chromosome, plasmid, etc.) with which a genetic function is associated.
- a gene is a hereditary unit, for example of an organism, comprising a polynucleotide sequence (e. g., a DNA sequence for mammals) that occupies a specific physical location (a "gene locus” or “genetic locus”) within the genome of an organism.
- a gene can encode an expressed product, such as a polypeptide or a polynucleotide (e. g., tRNA).
- a gene may define a genomic location for a particular event/function, such as the binding of proteins and/or nucleic acids (e. g., phage attachment sites), wherein the gene does not encode an expressed product.
- a gene comprises coding sequences, such as polypeptide encoding sequences, and non-coding sequences, such as promoter sequences, poly-adenlyation sequences, transcriptional regulatory sequences (e. g., enhancer sequences).
- Many eukaryotic genes have "exons" (coding sequences) interrupted by "introns" (non-coding sequences).
- a gene may share sequences with another gene (s) (e. g., overlapping genes).
- a "coding sequence” or a sequence which "encodes” a selected polypeptide is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or “control elements").
- the boundaries of a coding sequence are determined by a start codon at the 5'
- a coding sequence can include, but is not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic DNA sequences from viral or procaryotic DNA, and even synthetic DNA sequences.
- a transcription termination sequence may be located ' to the coding sequence. Transcription and translation of coding sequences are typically regulated by "control elements", including, but not limited to, transcription promoters, transcription enhancer elements, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5' to the coding sequence), and translation termination sequences.
- a nucleic acid for use in the invention which comprises a coding sequence may be contained in an expression vector.
- a suitable expression vector comprises nucleotide sequences, for example a coding sequence encoding a desired peptide or polypeptide.
- Such expression vectors are routinely constructed in the art of molecular biology and may for example involve the use of plasmid or cosmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression.
- Other suitable vectors would be apparent to persons skilled in the art.
- a nucleic acid suitable for use in the invention may also be inserted into a vector in an antisense orientation in order to provide for the production of antisense RNA.
- a “promoter” is a nucleotide sequence which initiates transcription of a polypeptide-encoding polynucleotide. Promoters can include inducible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters
- promoter or "control element” includes full-length promoter regions and functional (e. g., controls transcription or translation) segments of these regions.
- a polynucleotide, especially a coding, for use in a complex of the invention is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a control sequence such as a promoter, "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence.
- the control sequence will typically comprise a promoter and optionally also comprise other types of control sequence, for example an enhancer and/or terminator.
- An enhancer is any polynucleotide sequence capable of increasing the level of transcription initiating from a promoter and may act on a cis or trans basis.
- a terminator is any polynucleotide sequence capable of promoting dissociation of an RNA polymerase from the said sequence.
- a control sequence may be positioned 5', 3' or internal to (for example in an intron) a coding sequence.
- a coding sequence may be operably linked to more than one control sequence, for example two, three, four or five control sequences. Such multiple control sequences may be positioned, for example, entirely 5' to the coding sequence. However, more typically control sequences will be located both 5' and 3' to the coding sequence, with optional internal control sequences. Control sequences may be derived from any suitable source and may be generated by recombinant techniques or synthetic means.
- the vectors may be for example, plasmid, virus or phage vectors provided with a origin of replication, optionally a promoter for the expression of the desired polynucleotide and optionally a regulator of the promoter.
- the vectors may contain one or more selectable marker genes, for example an ampicillin resistence gene in the case of a bacterial plasmid or a resistance gene for a fungal vector.
- Vectors may be used in vitro, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell.
- the vectors may also be adapted to be used in vivo, for example in a method of gene therapy or vaccination.
- Suitable nucleic acids for use in a complex of the invention may be obtained from natural sources, or may be produced recombinantly or by chemical synthesis. They may be modified, for example, to comprise a sequence encoding a specific function, for example, a nuclear localisation sequence.
- a nucleic acid in a complex of the invention may be selected for use in gene therapy, in gene vaccination, in anti-sense therapy or in therapy by interfering RNA.
- the nucleic acid component is generally presented in the form of a nucleic acid insert in a plasmid or vector. In some cases, however, it is not necessary to incorporate the nucleic acid component in a vector in order to achieve expression.
- gene vaccination and anti-sense therapy can be achieved using a naked nucleic acid.
- the nucleic acid is generally DNA but RNA may be used in some cases, for example, in cancer vaccination.
- the nucleic acid in a complex of the invention may be or may relate to a gene that is the target for particular gene therapy or may be a molecule that can function as a gene vaccine or as an anti-sense therapeutic agent.
- the nucleic acid may be or correspond to a complete full-length coding sequence or may be part of a coding sequence.
- a nucleic acid may be selected to act via an antisense mechanism or via an
- RNA interference mechanism An antisense RNA may comprise a polynucleotide which has substantial complementarity to all or part of its target mRNA.
- a polynucleotide which has substantial sequence complementarity to all or part of its target mRNA is typically one which is capable of hybridizing to that mRNA. If the RNA has substantial complementarity to a part of its target mRNA of, it generally has substantial complementarity to a contiguous set of nucleotides within that mRNA.
- a vector which allows for the expression of a polynucleotide which has substantial sequence complementarity to all or part of the target mRNA (i.e. a polynucleotide which can hybridize to that mRNA). This results in the formation of an RNA-RNA duplex which may result in the direct inhibition of translation and/or the destabilization of the target message, by rendering it susceptibility to nucleases, for example.
- the vector will typically allow the expression of a polynucleotide which hybridizes to the ribosome binding region and/or the coding region of the target mRNA.
- an oligonucleotide may be delivered which is capable of hybridizing to the target mRNA.
- Antisense oligonucleotides are postulated to inhibit target gene expression by interfering with one or more aspects of RNA metabolism, for example processing, translation or metabolic turnover.
- Chemically modified oligonucleotides may be used and may enhance resistance to nucleases and/or cell permeability.
- the vector is capable of expressing a polynucleotide which has substantial sequence complementarity to all of part of the target mRNA.
- Such a polynucleotide will be capable of hybridizing to the target mRNA.
- such a polynucleotide will be an RNA molecule.
- Such a polynucleotide may hybridize to all or part of the target mRNA.
- the polynucleotide will be complementary to all of or part of such an mRNA.
- the polynucleotide may be the exact complement of such an mRNA.
- absolute complementarity is not required and preferred polynucleotides which have sufficient complementarity (i.e. substantial complementarity) to form a duplex having a melting temperature of greater than 40°C under physiological conditions are particularly suitable for use in the present invention.
- the polynucleotide may be a polynucleotide which hybridises to the target mRNA under conditions of medium to high stringency, such as 0.03M sodium chloride and 0.03M sodium citrate at from about 50 to about 60 degrees centigrade.
- the polynucleotide hybridizes to a coding region of the target mRNA.
- a polynucleotide may be employed which hybridises to all or part of the 5'- or 3 '-untranslated region of such an mRNA.
- the polynucleotide will typically be at least 40, for example at least 60 or at least 80, nucleotides in length and up to 100, 200, 300, 400, 500, 600 or 700 nucleotides in length or even up to a few nucleotides, such as five or ten nucleotides, shorter than the full-length mRNA.
- the polynucleotide, i.e.
- the "antisense" polynucleotide may be expressed in a cell from a suitable vector.
- a suitable vector is typically a recombinant replicable vector comprising a sequence which, when transcribed, gives rise to the polynucleotide (typically an RNA).
- the sequence encoding the polynucleotide is operably linked to a control sequence which is capable of providing for the transcription of the sequence giving rise to the polynucleotide.
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a control sequence "operably linked" to a sequence giving rise to an antisense RNA is ligated in such a way that transcription of the sequence is achieved under conditions compatible with the control sequences.
- the vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for transcription to occur and optionally a regulator of the promoter.
- the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of bacterial plasmid or a neomycin resistance gene for a mammalian vector.
- Vectors may be used in vitro, for example for the production of antisense RNA, or used to transfect or transform a host cell.
- the vector will typically be adapted for use in vivo, for example in a method of gene therapy.
- Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed.
- mammalian promoters such as ⁇ -actin promoters
- Viral promoters may also be used, for example the Moloney murine leukaemia virus long te ⁇ ninal repeat (MMLV LTR), the promoter rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adeno virus promoters. All these promoters are readily available in the art.
- Preferred promoters are tissue specific promoters, for example promoters driving expression specifically within vascular tissue.
- a suitable oligonucleotide will typically have a sequence such that it will bind to the target mRNA. Therefore, it will typically have a sequence which has substantial complementarity to a part of such an mRNA.
- a suitable oligonucleotide will typically have substantial complementarity to a contiguous set of nucleotides within the target mRNA.
- An antisense oligonucleotide will generally be from about 6 to about 40 nucleotides in length. Preferably it will be from 12 to 20 nucleotides in length.
- the oligonucleotide used will have a sequence that is absolutely complementary to the sequence. However, absolute complementarity may not be required and in general any oligonucleotide having sufficient complementarity (i.e. substantial complementarity) to form a stable duplex (or triple helix as the case may be) with the target nucleic acid is considered to be suitable.
- the stability of a duplex (or triplex) will depend inter alia on the sequence and length of the hybridizing oligonucleotide and the degree of complementarity between the antisense oligonucleotide and the target sequence. The system can tolerate less complementarity when longer oligonucleotides are used.
- oligonucleotides especially oligonucleotides of from 6 to 40 nucleotides in length, which have sufficient complementarity to from a duplex having a melting temperature of greater than 40°C under physiological conditions are particularly suitable for use in the present invention.
- the polynucleotide may be a polynucleotide which hybridises to under conditions of medium to high stringency such as 0.03M sodium chloride and 0.03M sodium citrate at from about 50 to about 60 degrees centigrade.
- Antisense oligonucleotides may be chemically modified.
- phosphorothioate oligonucleotides may be used.
- Other deoxynucleotide analogs include methylphosphonates, phosphora idates, phosphorodithioates, N3T5'- phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methylribonucleotide methylphosphonates.
- MBOs Mixed backbone oligonucleotides
- MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed segments of modified oligodeoxy- or oligoribonucleotides.
- MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'- O-alkyloligoribonucleotides .
- An nucleic acid suitable for use in the invention may act via an RNA interference (RNAi) mechanism.
- RNAi RNA interference
- Such a nucleic acid is typically a double-stranded RNA and has a sequence substantially similar to part of the target mRNA.
- Preferred nucleic acids of this type are typically short, for example 15mers to 25mers, in particular 18mers to 23mers. These short nucleic acids may be referred to as interfering RNAs (iRNAs).
- iRNAs interfering RNAs
- the use of short nucleic acids of the type described above is preferred because such inhibitors do not appear to trigger viral defence mechanisms of higher organisms.
- Such nucleic acids can be used to inhibit translation of the mRNA.
- small fragments of sequence encoding the target gene product may be provided, cloned back to back in a suitable vector.
- the vectors described above are suitable for expression of such back to back sequences. Expression of the sequence leads to production of the desired double-stranded RNA.
- a nucleic acid suitable for use in a complex of the invention may comprise a sequence which encodes an antigen.
- An antigen is a molecule which contains one or more epitopes that will stimulate a host's immune system to make a cellular antigen- specific immune response, or a humoral antibody response.
- a suitable nucleic acid sequence encoding an antigen can be derived from any known organism or pathogen, e.g. a virus, a bacterium, a parasite, a plant, a protozoan, or a fungus. The term also includes tumor antigens.
- the antigen typically comprises one or more T cell epitopes. "T cell epitopes"are generally those features of a peptide structure capable of inducing a T cell response.
- T cell epitopes comprise linear peptide determinants that assume extended conformations within the peptide-binding cleft of MHC molecules, (Unanue et al. Science 236, 551- 557, 1987).
- a T cell epitope is generally a peptide having about 8-15, preferably 5-10 or more amino acid residues.
- a nucleic acid suitable for use in a complex of the invention may encode such a T cell epitope.
- a nucleic acid suitable for use in a complex of the invention may encode a protein that is commercially useful, for example industrially or scientifically useful, for example an enzyme; pharmaceutically useful, for example, a protein that can be used therapeutically or prophylactically as a medicament or vaccine; or diagnostically useful, for example, an antigen for use in an ELISA.
- a biologically-active material for use in a complex of the invention may be a peptide or polypeptide. Suitable peptides/polypeptides are those encoded by one of the nucleic acids set out above.
- the peptide/polypeptide may be, for example, one that is absent or deficient in a genetic disease or an antigen or immunogen.
- the peptide/polypeptide may be, for example, a natural hormone such as tissue insulin, calcitonin and human growth hormone, or a synthetic analogue of such a natural hormone.
- peptides/polypeptides which may be used in a complex of the invention include interleukin-2, tumor necrosis factor, tissue plasminogen activator, factor VIII, erythropoietin, growth factors such as epidermal growth factor, growth hormone releasing factor, neural growth factor and toxic peptides such as ricin, diphtheria toxin, or cobra venom factor, capable of eliminating diseased or malignant cells. Fragments of any of the polypeptides mentioned above may also be used in a complex of the invention.
- Peptides/polypeptides suitable for use in a complex of the invention may be chemically modified, e.g. post-translationally modified.
- they may be glycosylated or comprise modified amino acid residues.
- They may also be modified by the addition of histidine residues to assist their purification or by the addition of a signal sequence to promote insertion into the cell membrane.
- a biologically-active material for use in a complex of the invention may be a small molecule.
- Preferred small molecules are therapeutic agents, for example steroids such as hydrocortisone, fluocinolone acetonide, fluocinonide and dexamethasone, non-steroidal anti-inflammatory agents such as 1-acetylsalicyclic acid, antiviral nucleosides such as AZT, acyclovir and gancyclovir, or phospholipid derivatives of such antiviral nucleosides, antibiotics, anaesthetic agents, cytostatic agent or immunomodulators.
- a complex ofthe invention may also contain a sunscreen or a cosmetic.
- a complex of he invention will typically comprise a ratio of from 0.25 to 12: 1 by weight of a lipid ofthe invention: a biologically-active material (such as a nucleic acid), for example a ratio of from 0.5 to 8: 1 by weight of a lipid ofthe invention: a biologically-active material, such as from 0.75 to 4: 1 weight of a lipid of the invention: a biologically-active material, for example from 1 to 2: 1 by weight of a lipid ofthe invention: a biologically-active material.
- a biologically-active material such as a nucleic acid
- a complex ofthe invention may comprise an integrin-binding component, for example an integrin-binding peptide.
- An integrin-binding component suitable for use in a complex ofthe invention is any such component which is capable of binding specifically to integrins found on the surface of cells.
- the integrin-binding component may be a naturally occurring integrin-binding ligand, for example, an extra-cellular matrix protein, a viral capsid protein, 'the bacterial protein invasin, a snake venom disintegrin protein, or an integrin-binding fragment of any such protein.
- Such integrin-binding proteins and fragments thereof may be obtained from natural sources or by recombinant techniques, but they are difficult to synthesise and purify in large amounts, they require conjugation directly to DNA or RNA or to poly cationic elements for DNA or RNA binding, and are immunogenic in vivo.
- integrin-binding peptides it is thus preferable to use integrin-binding peptides, in particular because of their ease of synthesis, purification and storage, their potential for chemical modification, and their potentially low immunogenicity in vivo.
- Examples of integrin-binding peptides are given in Verfaille, 1994 #635; Wang, 1995 #645; Wunschz, 1991 #539; Pierschbacher, 1984 #314; Massia, 1992 #86; Clements et al. J. Cell Science 107, 2127-2135, 1994; Lu et al, Biochemistry J.
- peptides containing the conserved amino acid sequence arginine-glycine-aspartic acid bind with high affinity to integrins.
- peptides comprising the RGD sequence are particularly useful.
- the affinity between integrin and peptide ligands is influenced by the amino acid sequence flanking the RGD domain.
- Peptides having a cyclic region in which the conformational freedom ofthe RGD sequence is restricted generally have a higher affinity for integrin receptors than do their linear counterparts.
- Such cyclic peptides are particularly preferred.
- Cyclic peptides may be formed by the provision of two cysteine residues in the peptide, thus enabling the formation of a disulphide bond.
- a cysteine residue may be separated from the RGD sequence by one or more residues, for example, up to six residues, or may be immediately adjacent to the RGD sequence, although preferably both cysteines are not immediately adjacent to the ends ofthe RGD sequence.
- CRGDMFGC An example of an amino acid sequence that will permit cyclisation by disulphide bond formation is CRGDMFGC.
- a peptide that consists of or comprises the sequence CRGDMFGC may advantageously be used as an integrin-binding peptide according to the present invention.
- Examples of peptides that comprises the sequence CRGDMFGC and that are effective integrin-binding ligands are the peptides GGCRGDMFGC, GGCRGDMFGCG, GGCRGDMFGCA and GACRGDMFGCA.
- the peptide GACDCRGDCFCA has the potential to form two disulphide bonds for stabilising the RGD loop. That peptide and others having the potential to form two RGD-stabilising disulphide bonds, may be particularly useful as integrin-binding ligands according to the present invention.
- a further useful peptide is GACATRWARECG.
- not all integrin-binding peptides contain the conserved RGD sequence.
- the peptides GACRRETAWACA, GACRRETAWACG and XSXGACRRETAWACG are integrin-specific peptides.
- peptides comprising the sequence CRRETTAWAC or CRRETAWAC may be used, as may other non- RGD peptides, particularly those that have the potential for disulphide bond formation.
- Peptide sequences may be designed on the basis of known ligands, for example, on the basis of integrin-binding domains of naturally-occurring integrin- binding ligands, or on the basis of known peptides that bind to integrins.
- integrins are a family of heterodimeric proteins found on the surface of cells. They consist of several different ⁇ and ⁇ subunits. Some integrins are found on many types of cells, others are more specific, for example, ⁇ 5 and ⁇ v integrins are widespread and are found on a diverse range of cells. Integrin-binding ligands can vary in their affinity for different integrins. For example, GACRGDMFGCA (peptide 1) has affinity for ⁇ 5 and av integrins but is non-specific (O'Neil et al. 1992, supra; Hart et al. 1997, supra).
- GACDCRGDCFCA (peptide 5) has high affinity for integrin ⁇ v but is not ⁇ v-specific (Koivunen et al. 1995, supra; Hart et al. 1997, supra).
- GACRRETAWACG which does not contain the conserved RGD region, is ⁇ 5 ⁇ l-specific (Koivunen et al. 1995, supra).
- Various integrin-binding peptides and their integrin specificity are set out below:
- GA-CXCG where X is SERSMNF, YGLPHKF, PSGAARA, VKSMVTH or LQHKSMP.
- Alternative oligopeptides may be used in conjunction with or instead of an integrin-binding peptide, for example alternative targetting ligands, such as oligopeptides identified by panning with phage-based peptide-display libraries; membrane-active peptides such as melittin; fragments ofthe HIV tat protein; single chain Fv regions of antibodies; VP22; peptides containing nuclear localisation sequences; mitochondrial localisation sequences; and peptides based on the influenza virus haemagglutinin protein.
- alternative targetting ligands such as oligopeptides identified by panning with phage-based peptide-display libraries; membrane-active peptides such as melittin; fragments ofthe HIV tat protein; single chain Fv regions of antibodies; VP22; peptides containing nuclear localisation sequences; mitochondrial localisation sequences; and peptides based on the influenza virus haemagglutinin protein.
- a complex ofthe invention will typically comprise a ratio of from 0.25 to 4: 4 by weight of a lipid ofthe invention: an integrin-binding peptide, for example a ratio of from 0.5 to 2: 4 by weight of a lipid ofthe invention: an integrin-binding peptide, such as from 0.75 to 1 : 4 by weight of a lipid ofthe invention: an integrin- binding peptide.
- complexes ofthe invention will comprise a cationic component, such as a cationic polymer. This is particularly the case for complexes where the biologically-active material is a nucleic acid.
- Cationic polymers suitable for use in the invention are typically capable of binding to a nucleic acid.
- Especially preferred cationic polymers are capable of condensing nucleic acids into a particle with a diameter of from about 50nm to about 150nm.
- suitable cationic polymers are low molecular weight polymers and the number of positive charges per polymer molecule is typically from about 7 to about 50, preferably from about 7 to about 25 or more preferably from about 12 to about 16.
- Suitable cationic polymers may have any number of cationic monomers, although generally the polymer must retain the ability to bind nucleic acids. For example, from 3 to 100 cationic monomers may be present, for example, from 10 to 20.
- Suitable polymers include oligolysine, for example having from 10 to 20 lysine residues, for example, from 15 to 17 residues, especially 16 residues, i.e. [K] 16 .
- poly-L-lysine which has a molecular weight of 3.4kDa (and which has an average of 16 positive charges per molecule) is preferred.
- suitable polymers include polyethylenimine (PEI) which has a molecular weight of 2kDa (with an average of 12 positive charges per molecule at neutral pH) and polyamidoamine dendrimers.
- PEI polyethylenimine
- Suitable peptides are disclosed in USSN 09/424656 and 08/836786, the disclosures of which are incorporated herein by reference. The polymers pLL and pEI will condense RNA and DNA in water or 1 OmM
- cationic polymers with a pKa of greater than 9.0 generally do not possess endosomolytic activity and require the presence of an endosome-disrupting agent, for example chloroquine, to enable them to gain access into the cytosol.
- the poly cationic component may advantageously be linked or otherwise attached to the integrin-binding component.
- a polycationic polymer may be chemically bonded to an integrin-binding component, for example, by a peptide bond in the case of an oligolysine. Other types of suitable bonds are thioether and disulphide bonds.
- the polycationic component may be linked at any position ofthe integrin-binding component.
- Preferred combinations of integrin- binding component and polycationic polymer are an oligolysine, especially [K] 16 , linked via a peptide bond to an intergin-binding peptide peptide, for example any one ofthe peptides set out described above.
- a complex ofthe invention will typically comprise a ratio of from 0.25 to 4: 4 by weight of a lipid of the invention: a polycationic component (such a polycationic peptide), for example a ratio of from 0.5 to 2: 4 by weight of a lipid ofthe invention: a polycationic component, such as from 0.75 to 1 : 4 by weight of a lipid ofthe invention: a polycationic component.
- a polycationic component such a polycationic peptide
- the ratio of a lipid ofthe invention to the combined peptide is as given above for an integrin-binding peptide and polycationic component individually.
- Agents other than peptides may also be introduced onto the condensing cationic polymer, for example saccharide residues or lipids, to modulate solubility and interaction of formulations with biological proteins, fluids, membranes and cells, including to specific receptors.
- a neutral lipid may be used in a complex ofthe invention.
- a complex ofthe invention may be free of a neutral lipid.
- Any neutral lipid may be used in a complex ofthe invention, although typically those that have membrane destabilising properties are preferred.
- An example of a suitable neutral lipid which has membrane destabilising properties is dioleyl phosphatidylethanolamine (DOPE).
- DOPE dioleyl phosphatidylethanolamine
- DOPE has membrane destabilising properties sometimes referred to as "fusogenic" properties.
- the ratio of neutral lipid: a lipid ofthe invention is from about 0.5 to 2: 1 for example 1: 1.
- a complex ofthe invention may be prepared by a process which comprises admixing the components ofthe complex. Although, the components may be admixed in any order, it is generally preferable that the lipid component is not added last. In the case where there is a combined integrin-binding peptide/polycationic component, it is generally preferable to combine the components in the following order: lipid; combined integrin-binding peptide/polycationic component; biologically-active material.
- the components of a complex of the invention are preferably admixed in the amounts set out above.
- a typical complex ofthe invention may be prepared by admixing a lipid ofthe invention combined integrin-binding peptide-cationic component (such as
- the invention also provides a mixture which comprises: a lipid; and one or more of an integrin-binding peptide, a polycationic component and a neutral lipid. All ofthe components of such a mixture may be as set out above.
- a mixture may be used to produce a biologically-active material containing complex ofthe invention by the incorporation of a biologically-active material with the mixture, for example by admixture.
- the present invention further provides a process for the production of a complex ofthe present invention, which comprises admixing a biologically-active material with a mixture ofthe invention.
- a process for the production of a complex ofthe present invention which comprises admixing a biologically-active material with a mixture ofthe invention.
- the preferred components, preferred combinations of components, preferred ratios of components and preferred order of mixing, both with regard to the mixture and to the production of a complex are as described above in relation to the complex ofthe invention.
- a complex ofthe invention may be used in a process for transfecting a cell with a biologically-active material.
- a host cell is contacted with a complex ofthe invention.
- a complex ofthe invention may also be used in a process for expressing a nucleic acid in a host cell.
- Such a process comprises contacting the host cell with a complex ofthe invention which comprises a nucleic acid.
- the host cell is then subjected to conditions that enable the cell to express the nucleic acid, for example it is cultured in a medium which allows expression ofthe nucleic acid.
- a complex ofthe invention may be further used in a process for the production of a polypeptide.
- a host cell is transfected with a nucleic acid using the method set out above.
- the transfection is carried out under conditions suitable for expression ofthe polypeptide encoded by the nucleic acid or, alternatively, the transfected cell is transferred to conditions suitable for expression ofthe polypeptide encoded by the nucleic acid.
- the polypeptide may then be recovered from the host cell or from the culture medium.
- the host cell may be any host cell.
- the cell may be a prokaryotic cell or a eukaryotic cell.
- the cell may be from a bacterium, a mycobacterium, a protozoan, a parasite, a fungus a plant or an animal. Suitable animal cells are mammalian cells, for example human cells. All ofthe methods may be carried out in vivo, in vitro or ex vivo. Also, cells may be obtained from a host, transfected according to the method set out above, and then returned to the host.
- the invention also provides a cell transfected with a complex ofthe invention and progeny cells derived from such a transfected cell.
- kits for delivery of a biologically-active material to a cell which kit comprises a mixture ofthe invention or components suitable for the preparation of a mixture of the invention.
- a kit may comprise a lipid of formula (I) or (II) as set out above and one or more of an integrin-binding peptide, a polycationic component and a neutral lipid (all as described above).
- the kit may also comprise a biologically- active material.
- the kit may comprise a nucleic acid, optionally in the form of a plasmid or vector which may be empty or comprise a coding sequence.
- a kit ofthe invention may comprise appropriate buffers and/or control cells. Also, a kit ofthe invention may comprise appropriate packaging and instructions for using the kit in one ofthe methods set out above. Thus, the instructions may indicate the preferred ratios ofthe components and the preferred order of admixing the components, for example as described above.
- a kit may be used for producing a complex suitable for use in gene therapy, vaccination, antisense of iRNA therapy. Alternatively, it may be used for producing a complex suitable for transfecting a host cell with a nucleic acid encoding a commercially useful protein, i.e. to produce a so- called "cell" factory.
- a complex ofthe invention may be used in a method of treatment or vaccination.
- Treatment according to the invention may be prophylactic or therapeutic.
- a complex ofthe invention may be used in a method for nucleic acid transfer, for example in a method of treatment ofthe human or animal body by therapy.
- a complex ofthe invention may also be used for the manufacture of a medicament for use in nucleic acid transfer, for example in treatment ofthe human or animal body by therapy, especially in the treatment of a condition caused by or related to a genetic defect or modification.
- the condition of a patient suffering from such a condition can be improved by administration of a complex ofthe invention.
- a therapeutically effective amount of a complex ofthe invention may be given to a host in need thereof.
- the host may be a human or non- human animal.
- Targets for gene therapy are well known and include monogenic disorders, for example, cystic fibrosis, various cancers, and infections, for example, viral infections, for example, with HIV.
- transfection with the p53 gene offers great potential for cancer treatment.
- Targets for gene vaccination are also well known, and include vaccination against pathogens for which vaccines derived from natural sources are too dangerous for human use and recombinant vaccines are not always effective, for example, hepatitis B virus, HIV, HCV and herpes simplex virus.
- Targets for anti-sense therapy are also known. Further targets for gene therapy and anti-sense therapy are being proposed as knowledge ofthe genetic basis of disease increases, as are further targets for gene vaccination.
- a complex ofthe invention may be used in vaccination.
- a complex of the invention may be used to deliver an antigen or a nucleic acid encoding an antigen. That is to say, a complex ofthe invention may be used in gene vaccination.
- a complex ofthe invention may be used to elicit an immune response against a wide variety of antigens for the treatment and/or prevention of a number of conditions mcluding, but not limited to, cancer, allergies, toxicity and infection by pathogens such as viruses, bacteria, fungi, and other pathogenic organisms.
- Suitable viral antigens and nucleic acids encoding such antigens for use in the complexes of the invention include, but are not limited to, those obtained or derived from the hepatitis family of viruses, including hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis virus (HDV), hepatitis E virus (HEV) and hepatitis G virus (HGV).
- HCV hepatitis A virus
- HBV hepatitis B virus
- HCV hepatitis C virus
- HDV delta hepatitis virus
- HEV hepatitis E virus
- HGV hepatitis G virus
- proteins, and nucleic acids encoding such proteins, from the herpesvirus family can be used as antigens in the present invention, including proteins derived from herpes simplex virus (HSV) types 1 and 2, such as HSV-1 and HSV-2 glycoproteins gB, gD and gH; antigens from varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) including CMV gB and gH; and antigens from other human herpesviruses such as HHV6 and
- HHV7 See, e. g. Chee et al. (1990) Cytomegaloviruses (J. K. McDougall, ed., Springer Verlag, pp. 125-169; McGeoch et al. (1988) J. Gen. Virol. 69: 1531-1574; U. S. Patent No. 5,171,568; Baer et al. (1984) Nature 310: 207-211; and Davison et al. (1986) J. Gen. Virol.
- HIV antigens such as gpl20 molecules for a multitude of HIV- 1 and HIV-2 isolates, including members ofthe various genetic subtypes of HIV, are known and reported (see, e. g., Myers et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); and Modrow et al. (1987) J. Virol. 61: 570-578) and antigen-containing nucleic acid sequences derived or obtained from any of these isolates will find use in the present invention.
- HIV Human immunodeficiency virus
- immunogenic proteins derived or obtained from any ofthe various HIV isolates will find use herein, including nucleic acid sequences encoding one or more ofthe various envelope proteins such as gap 160 and gp41, gag antigens such as p24gag and p55gag, as well as proteins derived from the pol, env, tat, vif, rev, nef, vpr, vpu and LTR regions of HIV.
- Antigens derived or obtained from other viruses will also find use herein, such as without limitation, antigens from members ofthe families Picornaviridae (e. g., polioviruses, rhinoviruses, etc.); Caliciviridae; Togaviridae (e. g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae (e. g., rotavirus, etc.);
- Birnaviridae Rhabodoviridae (e. g., rabies virus, etc.); Orthomyxoviridae (e. g., influenza virus types A, B and C, etc.); Filoviridae; Paramyxoviridae (e. g., mumps virus, measles virus, respiratory syncytial virus, parainfluenza virus, etc.); Bunyaviridae; Arenaviridae; Retroviradae (e.
- HTLV-I HTLV-11
- HIV-1 also known as HTLN-111, LAV, ARV, hTLR, etc.
- HIV-1CM235 HIV-1
- HIV-2 among others
- simian immunodeficiency virus (SIV) Papillomavirus, the tick-bourne encephalitis viruses; and the like.
- SIV simian immunodeficiency virus
- Papillomavirus the tick-bourne encephalitis viruses; and the like. See, e. gNirology, 3rd Edition (W. K. Joklik ed. 1988); Fundamental Virology, 2 nd Edition (B. ⁇ . Fields and D. M. Knipe, eds. 1991), for a description of these and other viruses.
- Nucleic acid sequences encoding such antigens may of course also be used in a complex of the invention.
- a selected antigen is obtained or derived from a viral pathogen that typically enters the body via a mucosal surface and is known to cause or is associated with human disease, such as, but not limited to, HIN (AIDS), influenza viruses (Flu), herpes simplex viruses (genital infection, cold sores, STDs), rotaviruses (diarrhea), parainfluenza viruses (respiratory infections), poliovirus (poliomyelitis), respiratory syncytial virus (respiratory infections), measles and mumps viruses (measles, mumps), rubella virus (rubella), and rhinoviruses (common cold).
- HIN HIV
- influenza viruses Felu
- herpes simplex viruses geneital infection, cold sores, STDs
- rotaviruses diarrhea
- parainfluenza viruses respiratory infections
- poliovirus poliomyelitis
- respiratory syncytial virus respiratory
- Suitable bacterial and parasitic antigens can be obtained or derived from known causative agents responsible for diseases including, but not limited to, Diptheria, Pertussis, Tetanus, Tuberculosis, Bacterial or Fungal Pneumonia, Otitis Media, Gonnorhea, Cholera, Typhoid, Meningitis, Mononucleosis, Plague,
- antigens can be obtained or derived from unconventional pathogens such as the causative agents of kuru, Creutzfeldt- Jakob disease (CJD), scrapie, transmissible mink encephalopathy, and chronic wasting diseases, or from proteinaceous infectious particles such as prions that are associated with mad cow disease.
- CJD Creutzfeldt- Jakob disease
- scrapie transmissible mink encephalopathy
- chronic wasting diseases or from proteinaceous infectious particles such as prions that are associated with mad cow disease.
- nucleic acid sequences encoding such antigens may be used in a complex ofthe invention.
- pathogens from which antigens can be derived include M. tuberculosis, Chlamydia, ⁇ . gonorrhoeae, Shigella, Salmonella, Vibrio Cholera, Treponema pallidua, Pseudomonas, Bordetella pertussis, Brucella, Franciscella tulorensis, Helicobacter pylori, Leptospria interrogaus, Legionella pneumophila, Yersinia pestis, Streptococcus (types A and B), Pneumococcus, Meningococcus, Hemophilus influenza (type b), Toxoplasma gondic, Complylobacteriosis, Moraxella catarrhalis, Donovanosis, and Actinomycosis ; fungal pathogens including Candidiasis and Aspergillosis; parasitic pathogens including Taenia, Flukes, Roundworms, Amebiasis, Gi
- the present invention can also be used to provide a suitable immune response against numerous veterinary diseases, such as Foot and Mouth diseases, Coronavirus, Pasteurella multocida, Helicobacter, Strongylus vulgaris, Actinobacillus pleuropneumonia, Bovine viral diarrhea virus (BVDV), Klebsiella pneumoniae, E. coli, Bordetella pertussis, Bordetella parapertussis and brochiseptica.
- BVDV Bovine viral diarrhea virus
- Klebsiella pneumoniae E. coli
- Bordetella pertussis Bordetella parapertussis and brochiseptica
- nucleic acid sequences encoding an antigen as set out above may be used in a complex ofthe invention.
- a nucleotide sequence corresponding to (encoding) one or more of the above-listed antigen(s) is used in a complex ofthe invention.
- a complex ofthe invention may be in the form of a pharmaceutical composition which additionally comprises a pharmaceutically-acceptable carrier, diluent or excipient for example water or a physiologically-acceptable buffer.
- a vaccine composition comprises a complex ofthe invention and a pharmaceutically-acceptable carrier, diluent or excipient for example water or a physiologically-acceptable buffer.
- Such pharmaceutical and vaccine compositions may be supplied in any suitable dispenser, for example a puffer.
- a complex ofthe invention may be administered in a variety of dosage forms.
- the complexes can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
- the complexes may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
- the complexes may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.
- a complex of the invention may be formulated for simultaneous, separate or sequential use.
- a complex ofthe invention is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical carrier or diluent may be, for example, an isotonic solution.
- solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
- Liquid dispersions for oral administration may be syrups, emulsions or suspensions.
- the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
- Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
- Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
- a therapeutically effective amount of a complex is administered to a patient.
- the dose of a complex may be determined according to various parameters, especially according to the substance used; the age, weight and condition ofthe patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.
- the amount of nucleic acid delivered in a complex ofthe invention will be in the range of from l ⁇ g to lg, preferably from lOO ⁇ g to lOmg, according to the activity ofthe specific formulation, the age, weight and conditions ofthe subject to be treated, the type and severity ofthe degeneration and the frequency and route of administration.
- a single dose may be administered daily or alternatively, may multiple doses, for example two, three, four or five doses may be administered daily.
- the amount of nucleic acid referred to above may represent the total amount administered in the treatment regime or may represent each separate administration in the regime.
- the complex may be administered to the host in one or more administrations. Typically after the initial administration a "booster" can be given. Typically the host is given 1, 2, 3 or more separate administrations, each of which is separated by at least 12 hours, 1 day, 2 days, 7 days, 14 days, 1 month or more.
- lipids ofthe invention can be prepared by analogy with known methods.
- compounds of formula (I) can be prepared from 1,4- dibromobutanediol, using dimetl ylamine in methanol, according to the following reaction scheme.
- R in the above reaction scheme is, of course, defined as R 3 and R 4 above.
- X in the above reaction scheme is defined as X 1 and X 2 above.
- R in the above reaction scheme is defined as R 1 and R 2 above.
- step (1) is typically conducted stepwise.
- a first -N(R ) 2 moiety is added in a first step and a second -N(R ) 2 moiety is added in a second step.
- one ofthe hydroxy groups on compound (1) can be protected by a protecting group, prior to such a two stage reaction.
- the protecting group would, of course, then be removed after introduction ofthe first N(R ) 2 moiety and before the introduction ofthe second N(R ) 2 moiety.
- step 2 introduction ofthe XR moieties
- L-R wherein L is a leaving group such as a mesylate
- X is -O-CO-
- the XR moieties can be introduced by reaction with RCO 2 H, in the presence of EDCl, DMAP, ttiethylamine and DCM.
- the reaction is effected in a dark environment at room temperature.
- one XR moiety is introduced in a first step and a second XR moiety is introduced in a second step.
- One ofthe hydroxy groups on compound (2) can, if necessary, be protected prior to such a two stage reaction step by a standard hydroxy protecting group.
- the protecting group would of course then be removed after introduction ofthe first XR moiety and before introduction ofthe second XR moiety.
- R 7 in the above reaction scheme is, of course, defined as R 3 and R 4 above.
- X in the above reaction scheme is defined as X 1 and X 2 above.
- R in the above reaction scheme is defined as R 1 and R 2 above.
- Z in the above reaction scheme corresponds to the moiety -[A-Y] n R 4 except for the absence ofthe terminal -N + (R 4 ) 3 .
- the Z group can comprise carbamate protected amino moieties in place of quaternary ammonium moieties.
- the carbamate protected amino moieties in compound (8) can be deprotected and converted to quaternary ammonium moieties by standard methods. Quaternisation can, for example, be effected by reaction with R 4 -I.
- the compounds (8) are generally purified by recrystallisation.
- Q can be effected by standard techniques.
- Q when Q is -N + (R 3 ) 3 , it can be introduced by reacting compound (11) with a corresponding amino compound.
- the moiety N + (CH 3 ) 3 can be introduced by reaction with trimethylamine (45 wt% in H 2 O) in the presence of methanol in a sealed tube at 90°C for 24 hours.
- Example 1 Reaction Scheme I was followed to produce l,4-Di(trimethylammonium)-2,3-dioleoyloxy-butane; diiodide.
- the first step was the production of l,4-Di(dimethylamino)-2,3-butanediol
- Powdered sodium hydroxide (1.28 g, 32.0 mmol) was stirred in methanol (7 ml) at 0 °C.
- Dimethylamine hydrochloride (1.96 g, 24.0 mmol) was added followed by 1,4- Dibromo-2,3-butanediol (1.00 g, 4.00 mmol).
- the mixture was then heated to 80 °C in a sealed tube for 24 hr.
- the mixture was then concenttated in vacuo.
- the residue was re-dissolved in chloroform (25 ml) and the resulting mixture was filtered.
- the filtrate was concentrated in vacuo to yield the titled product as clear oil which solidifies to a colourless waxy solid upon refrigeration (0.69 g, 98%).
- Example 2 also illustrates Reaction Scheme 1.
- the first step of Example 1 was repeated, but in the second step the resulting butane diol was then used to synthesise an ether, rather than ester based lipid, namely l,4-Di(dimethylamino)-2,3-dioleyloxy- butane.
- the third step produced l,4-Di(ttime1hylammomum)-2,3-dioleyloxy-butane; diiodide
- Example 3 illustrates the use of Reaction Scheme 3. [2,3-Di-(oleyloxy)-propyl]-(3- bromo-propyl)-dimethyl-ammonium; bromide was prepared in a first step
- Example 5 illustrates Reaction Scheme 5. 2-[2-(2-Bromo-ethoxy)-ethoxy]-ethanol was produced in a first step.
- Tri (ethylene) glycol (4.50 g, 30.0 mmol) and hydrobromic acid solution (48%>, 5.09 ml, 45.0 mmol) were stirred in toluene (70 ml) at reflux for 72 hr. After cooling the solution was neutralized by the addition of saturated sodium hydrogencarbonate solution. Water (50 ml) was added and the resulting mixture was extracted with DCM (3 x 50 ml). The chlorinated extract was dried over anhydrous magnesium sulfate and concentrated in vacuo. No further purification was required and the above product was obtained as a yellow oil (2.29 g, 36 %).
- the activity of various compositions ofthe invention were measured in ⁇ AE cells using a Luciferase assay.
- RLU/mg refers to relative light units per mg of protein.
- the assay was carried out as follows: Lipid (10 mg/mL; 100 ⁇ L [1 mg of lipid]) in chloroform was placed into a glass vial (sterile). The solvents were removed in vacuo and further traces of chloroform were removed on the high vacuum for 24 h. Cationic Lipids were either formulated alone or with DOPE (mole ratio, 1 :1). Deionized water (1 mL; MilliQ) was added to the film, to generate 1 mg/mL solution of lipid in water. The mixture was allowed to hydrate at 4 °C for 24 h. After warming to 40 °C the mixture was sonicated to generate a clear solution (5 min approx). The resulting liposome formulations were stable for up to 3months.
- the components ofthe complex were mixed in a the required weight ratio.
- the lipid was initially mixed with the peptide and the resulting mixture was added to the plasmid DNA.
- Human airway epithelial cells were seeded for 24 h at 37 °C in complete growth medium in a 96 well plate. Transfection complexes were left to aggregate for 30 min and diluted to a concentration of 1 ⁇ g of DNA per 0.5 ml in OptiMEM (Life technologies). The medium was removed from each well and replaced with 0.5 ml of transfection complex and was allow to incubate for a further 4 h. The transfection complexes were removed and then replace with growth medium and the cells were allowed to incubate for 48 h.
- the transfected cells were washed with phosphate-buffered saline (PBS). Reporter lysis buffer (100 ⁇ l) (Promega) was added to each well and cooled to 4 ° C for 15 min. The cells were then assayed with a luciferase assay kit. The total light emission was measured for each well for 60 sec. The protein concentration of each sample was determined using a protein assay reagent and the activity expressed as relative light units per milligram of protein (RLU/mg).
- RLU/mg relative light units per milligram of protein
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0210538.5A GB0210538D0 (en) | 2002-05-08 | 2002-05-08 | Lipids and gene delivery |
GB0210538 | 2002-05-08 | ||
PCT/GB2003/001985 WO2003094974A1 (en) | 2002-05-08 | 2003-05-08 | Complexes for the delivery of biologically-active material to cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1506019A1 true EP1506019A1 (en) | 2005-02-16 |
Family
ID=9936285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03730315A Withdrawn EP1506019A1 (en) | 2002-05-08 | 2003-05-08 | Complexes for the delivery of biologically-active material to cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1506019A1 (en) |
JP (1) | JP2005530771A (en) |
AU (1) | AU2003240997A1 (en) |
GB (1) | GB0210538D0 (en) |
WO (1) | WO2003094974A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
WO2005117985A2 (en) * | 2004-06-02 | 2005-12-15 | Ucl Biomedica Plc | Lipopolyplex construct with an integrin binding peptide for delivery of nucleic acids, peptides or drugs |
CN115989511A (en) * | 2020-08-31 | 2023-04-18 | 武田药品工业株式会社 | Inference device, inference method, inference program, model generation method, inference service providing system, inference service providing method, and inference service providing program |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
EP0876611A1 (en) * | 1995-09-11 | 1998-11-11 | La Jolla Cancer Research Foundation | Molecules that home to a selected organ or tissue in vivo and methods of identifying same |
US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
AU7078396A (en) * | 1995-09-27 | 1997-04-30 | Regents Of The University Of California, The | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
GB9711115D0 (en) * | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
ATE549032T1 (en) * | 1999-03-26 | 2012-03-15 | Vical Inc | ADJUVANCE COMPOUNDS FOR IMPROVEMENT OF IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES |
DE60016205T2 (en) * | 1999-05-28 | 2005-12-01 | Vical, Inc., San Diego | CYTOFECTIN DIMERS AND METHOD FOR THEIR USE |
-
2002
- 2002-05-08 GB GBGB0210538.5A patent/GB0210538D0/en not_active Ceased
-
2003
- 2003-05-08 WO PCT/GB2003/001985 patent/WO2003094974A1/en active Application Filing
- 2003-05-08 EP EP03730315A patent/EP1506019A1/en not_active Withdrawn
- 2003-05-08 JP JP2004503057A patent/JP2005530771A/en active Pending
- 2003-05-08 AU AU2003240997A patent/AU2003240997A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO03094974A1 * |
Also Published As
Publication number | Publication date |
---|---|
GB0210538D0 (en) | 2002-06-19 |
WO2003094974A1 (en) | 2003-11-20 |
AU2003240997A1 (en) | 2003-11-11 |
JP2005530771A (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7507859B2 (en) | Functional synthetic molecules and macromolecules for gene delivery | |
US6218370B1 (en) | Glycerolipidic compounds used for the transfer of an active substance into a target cell | |
JP4176831B2 (en) | Lipopolyamine and its pharmaceutical use as transfection agent | |
US20030229037A1 (en) | Novel cationic amphiphiles | |
US20090221684A1 (en) | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | |
US7598421B2 (en) | Materials for the delivery of biologically-active material to cells | |
RU2739987C2 (en) | Multiple oligonucleotide fragments on a peptide carrier | |
WO1996001840A1 (en) | Cationic lipids for delivery of nucleic acids to cells | |
CN109503411B (en) | Tertiary amine cationic lipid derivative and application thereof in RNA drug delivery system | |
WO2023029928A1 (en) | Amino lipid and application thereof | |
WO2003094974A1 (en) | Complexes for the delivery of biologically-active material to cells | |
WO2005117985A2 (en) | Lipopolyplex construct with an integrin binding peptide for delivery of nucleic acids, peptides or drugs | |
JP6774965B2 (en) | Compounds as cationic lipids | |
AU750696B2 (en) | Use of a cationic polymer for the preparation of a complex with nucleic acid and related compositions | |
JPH09202799A (en) | Molecule having trfensaction ability | |
McKenzie | Development of sulfhydryl cross-linking peptides as novel low molecular weight nonviral gene delivery agents | |
Chen | Ortho ester-based pH-sensitive cationic lipoplexes for gene delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UCL BIOMEDICA PLC |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UCL BIOMEDICA PLC |
|
17Q | First examination report despatched |
Effective date: 20080915 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081202 |